Cellosaurus logo
expasy logo

Cellosaurus MG-63 (CVCL_0426)

[Text version]
Cell line name MG-63
Synonyms M-G63; MG63
Accession CVCL_0426
Resource Identification Initiative To cite this cell line use: MG-63 (RRID:CVCL_0426)
Comments Group: Space-flown cell line (cellonaut).
Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
Part of: COSMIC cell lines project.
Part of: MD Anderson Cell Lines Project.
Population: Caucasian.
Characteristics: Can be induced to differentiate by treating the cells with 1,25-dihydroxyvitamin D3 and TGF-beta. The cells do not differentiate into the mineralized state, but stop at the matrix maturation stage (PubMed=1577731).
Doubling time: 38 hours (PubMed=218153); 28.3 hours (PubMed=19363654); ~48 hours (PubMed=21519327).
Microsatellite instability: Stable (MSS) (Sanger).
Omics: Array-based CGH.
Omics: CNV analysis.
Omics: Deep exome analysis.
Omics: Deep quantitative proteome analysis.
Omics: DNA methylation analysis.
Omics: H3K4me1 ChIP-seq epigenome analysis.
Omics: H3K27ac ChIP-seq epigenome analysis.
Omics: Metabolome analysis.
Omics: Protein expression by reverse-phase protein arrays.
Omics: SNP array analysis.
Omics: Transcriptome analysis by microarray.
Omics: Transcriptome analysis by RNAseq.
Anecdotal: Have been flown in space on Foton-10 and Foton-M3 to study if differentiation is altered in microgravity (PubMed=9144345; PubMed=9600771; PubMed=24903274).
Caution: The reported STR profile from CLS of this cell line was changed in June 2019. Seven conflicts with other sources were resolved.
Misspelling: MGG3; PubMed=2823272; Note=In figure 4.
Derived from site: Metastatic; Bone, left femur; UBERON=UBERON_0000981.
Sequence variations
  • Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=19787792; ATCC).
  • Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=19787792).
HLA typing Source: PubMed=26589293
Class I
HLA-AA*01:01,01:01
HLA-BB*08:01,35:08
HLA-CC*07:01,07:01
Class II
HLA-DQDQA1*05:01,05:01
DQB1*02:02,03:04
HLA-DRDRB1*12:05,14:46

Source: CLS=300441
Class I
HLA-AA*01:01:01
HLA-BB*08:01:01
HLA-CC*07:01:01
Class II
HLA-DPDPB1*01:01:01,04:02:01
HLA-DQDQA1*05:01:01
DQB1*02:01:01
HLA-DRDRB1*03:01:01
Genome ancestry Source: PubMed=30894373

Origin% genome
African3.1
Native American0.69
East Asian, North2.05
East Asian, South0
South Asian5.07
European, North23.83
European, South65.26
Disease Osteosarcoma (NCIt: C9145)
Osteosarcoma (ORDO: Orphanet_668)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children:
CVCL_C9CX (MG-63-GAS-Luc2)CVCL_C6UW (MG-63/CISR8)CVCL_C6UX (MG-63/DOXR8)
CVCL_C6UY (MG-63/MTXR8)CVCL_C6UZ (MG-63/TRIR8)CVCL_IR36 (MG-63.3A)
CVCL_R705 (MG63.2)CVCL_9U34 (MG63/DXR1000)CVCL_WR53 (OSE-MG63)
Sex of cell Male
Age at sampling 14Y
Category Cancer cell line
STR profile Source(s): AddexBio; ATCC; CCRID; CLS; Cosmic-CLP; ECACC; JCRB; KCLB; PubMed=19787792; PubMed=25877200; RCB; TKG

Markers:
AmelogeninX,Y
CSF1PO10,12
D2S133817,24
D3S135815
D5S81811,12
D7S82010
D8S117913
D13S31711
D16S53911 (AddexBio; ATCC; CCRID; Cosmic-CLP; ECACC; PubMed=19787792; PubMed=25877200; RCB; TKG)
11,12 (CLS; JCRB)
D18S5116
D19S43313,14
D21S1130
FGA21,25
Penta D9,13
Penta E11,12
SE3320
TH019.3
TPOX8,11
vWA16,19

Run an STR similarity search on this cell line
Web pages https://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/m/cell-lines-detail-91.html
https://tcpaportal.org/mclp/
Publications

PubMed=883813; DOI=10.1128/AAC.12.1.11
Billiau A., Edy V.G., Heremans H., Van Damme J., Desmyter J., Georgiades J.A., De Somer P.
Human interferon: mass production in a newly established cell line, MG-63.
Antimicrob. Agents Chemother. 12:11-15(1977)

PubMed=218153; DOI=10.1159/000225298
Heremans H., Billiau A., Cassiman J.-J., Mulier J.C., De Somer P.
In vitro cultivation of human tumor tissues. II. Morphological and virological characterization of three cell lines.
Oncology 35:246-252(1978)

PubMed=2823272; DOI=10.1073/pnas.84.21.7716
Masuda H., Miller C., Koeffler H.P., Battifora H.A., Cline M.J.
Rearrangement of the p53 gene in human osteogenic sarcomas.
Proc. Natl. Acad. Sci. U.S.A. 84:7716-7719(1987)

PubMed=2233717; DOI=10.1128/mcb.10.11.5772-5781.1990
Diller L., Kassel J., Nelson C.E., Gryka M.A., Litwak G., Gebhardt M., Bressac B., Ozturk M., Baker S.J., Vogelstein B., Friend S.H.
p53 functions as a cell cycle control protein in osteosarcomas.
Mol. Cell. Biol. 10:5772-5781(1990)

PubMed=1577731; DOI=10.1016/S0021-9258(19)50371-4
Bonewald L.F., Kester M.B., Schwartz Z., Swain L.D., Khare A., Johnson T.L., Leach R.J., Boyan B.D.
Effects of combining transforming growth factor beta and 1,25-dihydroxyvitamin D3 on differentiation of a human osteosarcoma (MG-63).
J. Biol. Chem. 267:8943-8949(1992)

PubMed=7873286; DOI=10.1016/8756-3282(94)90305-0
Clover J., Gowen M.
Are MG-63 and HOS TE85 human osteosarcoma cell lines representative models of the osteoblastic phenotype?
Bone 15:585-591(1994)

PubMed=8617485; DOI=10.1016/S0046-8177(96)90115-X
Scotlandi K., Serra M., Manara M.C., Benini S., Sarti M., Maurici D., Lollini P.-L., Picci P., Bertoni F., Baldini N.
Immunostaining of the p30/32MIC2 antigen and molecular detection of EWS rearrangements for the diagnosis of Ewing's sarcoma and peripheral neuroectodermal tumor.
Hum. Pathol. 27:408-416(1996)

PubMed=9144345; DOI=10.1359/jbmr.1997.12.5.786
Carmeliet G., Nys G., Bouillon R.
Microgravity reduces the differentiation of human osteoblastic MG-63 cells.
J. Bone Miner. Res. 12:786-794(1997)

PubMed=9600771; DOI=10.1016/S8756-3282(98)00007-6
Carmeliet G., Nys G., Stockmans I., Bouillon R.
Gene expression related to the differentiation of osteoblastic cells is altered by microgravity.
Bone 22:139S-143S(1998)

PubMed=12645653; DOI=10.1016/S0165-4608(02)00685-4
Ozaki T., Neumann T., Wai D.H., Schaefer K.-L., van Valen F., Lindner N., Scheel C., Boecker W., Winkelmann W., Dockhorn-Dworniczak B., Horst J., Poremba C.
Chromosomal alterations in osteosarcoma cell lines revealed by comparative genomic hybridization and multicolor karyotyping.
Cancer Genet. Cytogenet. 140:145-152(2003)

PubMed=15736406
Pautke C., Schieker M., Tischer T., Kolk A., Neth P., Mutschler W., Milz S.
Characterization of osteosarcoma cell lines MG-63, Saos-2 and U-2 OS in comparison to human osteoblasts.
Anticancer Res. 24:3743-3748(2004)

PubMed=17981215; DOI=10.1016/j.cancergencyto.2007.08.003
Selvarajah S., Yoshimoto M., Maire G., Paderova J., Bayani J., Squire J.A., Zielenska M.
Identification of cryptic microaberrations in osteosarcoma by high-definition oligonucleotide array comparative genomic hybridization.
Cancer Genet. Cytogenet. 179:52-61(2007)

PubMed=19160414; DOI=10.1002/jcp.21667
Di Fiore R., Santulli A., Drago-Ferrante R., Giuliano M., De Blasio A., Messina C., Pirozzi G., Tirino V., Tesoriere G., Vento R.
Identification and expansion of human osteosarcoma-cancer-stem cells by long-term 3-aminobenzamide treatment.
J. Cell. Physiol. 219:301-313(2009)

PubMed=19363654; DOI=10.1007/s10585-009-9259-6
Su Y.-X., Luo X.-J., He B.-C., Wang Y., Chen L., Zuo G.-W., Liu B., Bi Y., Huang J.-Y., Zhu G.-H., He Y., Kang Q., Luo J.-Y., Shen J.-K., Chen J., Jin X.-Q., Haydon R.C., He T.-C., Luu H.H.
Establishment and characterization of a new highly metastatic human osteosarcoma cell line.
Clin. Exp. Metastasis 26:599-610(2009)

PubMed=19787792; DOI=10.1002/gcc.20717
Ottaviano L., Schaefer K.-L., Gajewski M., Huckenbeck W., Baldus S.E., Rogel U., Mackintosh C., de Alava E., Myklebost O., Kresse S.H., Meza-Zepeda L.A., Serra M., Cleton-Jansen A.-M., Hogendoorn P.C.W., Buerger H., Aigner T., Gabbert H.E., Poremba C.
Molecular characterization of commonly used cell lines for bone tumor research: a trans-European EuroBoNet effort.
Genes Chromosomes Cancer 49:40-51(2010)

PubMed=20164919; DOI=10.1038/nature08768
Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)

PubMed=21519327; DOI=10.1038/labinvest.2011.72
Mohseny A.B., Machado I., Cai Y.-P., Schaefer K.-L., Serra M., Hogendoorn P.C.W., Llombart-Bosch A., Cleton-Jansen A.-M.
Functional characterization of osteosarcoma cell lines provides representative models to study the human disease.
Lab. Invest. 91:1195-1205(2011)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=23144859; DOI=10.1371/journal.pone.0048262
Kresse S.H., Rydbeck H., Skarn M., Namlos H.M., Barragan-Polania A.H., Cleton-Jansen A.-M., Serra M., Liestol K., Hogendoorn P.C.W., Hovig E., Myklebost O., Meza-Zepeda L.A.
Integrative analysis reveals relationships of genetic and epigenetic alterations in osteosarcoma.
PLoS ONE 7:E48262-E48262(2012)

PubMed=23129384; DOI=10.1002/jcp.24272
Di Fiore R., Fanale D., Drago-Ferrante R., Chiaradonna F., Giuliano M., De Blasio A., Amodeo V., Corsini L.R., Bazan V., Tesoriere G., Vento R., Russo A.
Genetic and molecular characterization of the human osteosarcoma 3AB-OS cancer stem cell line: a possible model for studying osteosarcoma origin and stemness.
J. Cell. Physiol. 228:1189-1201(2013)

PubMed=24903274; DOI=10.1096/fj.14-249714
Guignandon A., Faure C., Neutelings T., Rattner A., Mineur P., Linossier M.-T., Laroche N., Lambert C., Deroanne C., Nusgens B., Demets R., Colige A., Vico L.
Rac1 GTPase silencing counteracts microgravity-induced effects on osteoblastic cells.
FASEB J. 28:4077-4087(2014)

PubMed=25382592; DOI=10.1021/pr500907d
Lamego I., Duarte I.F., Marques M.P.M., Gil A.M.
Metabolic markers of MG-63 osteosarcoma cell line response to doxorubicin and methotrexate treatment: comparison to cisplatin.
J. Proteome Res. 13:6033-6045(2014)

PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)

PubMed=25877200; DOI=10.1038/nature14397
Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., Neve R.M.
A resource for cell line authentication, annotation and quality control.
Nature 520:307-311(2015)

PubMed=26320182; DOI=10.18632/oncotarget.5177
Ren L., Mendoza A., Zhu J., Briggs J.W., Halsey C., Hong E.S., Burkett S.S., Morrow J.J., Lizardo M.M., Osborne T., Li S.Q., Luu H.H., Meltzer P.S., Khanna C.
Characterization of the metastatic phenotype of a panel of established osteosarcoma cells.
Oncotarget 6:29469-29481(2015)

PubMed=26589293; DOI=10.1186/s13073-015-0240-5
Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C.
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Genome Med. 7:118.1-118.7(2015)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

PubMed=29334376; DOI=10.1038/nm.4475
Morrow J.J., Bayles I., Funnell A.P.W., Miller T.E., Saiakhova A., Lizardo M.M., Bartels C.F., Kapteijn M.Y., Hung S., Mendoza A., Dhillon G., Chee D.R., Myers J.T., Allen F., Gambarotti M., Righi A., DiFeo A., Rubin B.P., Huang A.Y., Meltzer P.S., Helman L.J., Picci P., Versteeg H., Stamatoyannopoulos J.A., Khanna C., Scacheri P.C.
Positively selected enhancer elements endow osteosarcoma cells with metastatic competence.
Nat. Med. 24:176-185(2018)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3
Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)

PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010
Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Pan-cancer proteomic map of 949 human cell lines.
Cancer Cell 40:835-849.e8(2022)

PubMed=36480329; DOI=10.1002/adbi.202200194
Low K., Hills F., Roberts H.C., Stordal B.
Establishment and characterization of single and triple-agent resistant osteosarcoma cell lines.
Adv. Biol. (Weinh.) 7:e2200194.1-e2200194.13(2023)

Cross-references
Cell line collections (Providers) AddexBio; C0004007/4991
ATCC; CRL-1427
BCRC; 60279
BCRJ; 0173
CCTCC; GDC0074
CLS; 300441
ECACC; 86051601
ICLC; HTL99003
IZSLER; BS TCL 40
JCRB; IFO50108
KCB; KCB 200528YJ
KCLB; 21427
NCBI_Iran; C555
RCB; RCB1890
TKG; TKG 0294
Cell line databases/resources CLO; CLO_0007699
CLO; CLO_0007701
CLO; CLO_0050808
MCCL; MCC:0000323
CLDB; cl3462
CLDB; cl3463
CLDB; cl3464
CLDB; cl3465
CLDB; cl4934
cancercelllines; CVCL_0426
CCRID; 1101HUM-PUMC000080
CCRID; 3101HUMTCHu124
CCRID; 4201HUM-CCTCC00074
Cell_Model_Passport; SIDM00525
Cosmic-CLP; 908131
DepMap; ACH-000359
IGRhCellID; MG63
LINCS_LDP; LCL-1428
Lonza; 872
TOKU-E; 2429
Anatomy/cell type resources BTO; BTO:0001596
Biological sample resources BioSample; SAMN03471910
BioSample; SAMN03472771
BioSample; SAMN10988146
ENCODE; ENCBS091SUW
ENCODE; ENCBS462PMF
Chemistry resources ChEMBL-Cells; CHEMBL3308498
ChEMBL-Targets; CHEMBL614347
GDSC; 908131
PharmacoDB; MG63_924_2019
PubChem_Cell_line; CVCL_0426
Encyclopedic resources Wikidata; Q54905408
Experimental variables resources EFO; EFO_0002234
Gene expression databases ArrayExpress; E-MTAB-38
ArrayExpress; E-MTAB-783
ArrayExpress; E-MTAB-2706
ArrayExpress; E-MTAB-2770
ArrayExpress; E-MTAB-3610
GEO; GSM170251
GEO; GSM320828
GEO; GSM827317
GEO; GSM879217
GEO; GSM887314
GEO; GSM888390
GEO; GSM1670103
GEO; GSM1915004
GEO; GSM1915005
GEO; GSM1915006
GEO; GSM1915007
GEO; GSM2635311
GEO; GSM2635312
GEO; GSM1915033
GEO; GSM1915034
Polymorphism and mutation databases Cosmic; 755310
Cosmic; 908131
Cosmic; 931036
Cosmic; 931913
Cosmic; 1044085
Cosmic; 1070844
Cosmic; 1074394
Cosmic; 1082504
Cosmic; 1188475
Cosmic; 1529903
IARC_TP53; 21498
IARC_TP53; 21660
LiGeA; CCLE_145
Progenetix; CVCL_0426
Proteomic databases PRIDE; PXD030304
Sequence databases EGA; EGAS00001000610
EGA; EGAS00001000978
Entry history
Entry creation04-Apr-2012
Last entry update05-Oct-2023
Version number43